Yaw Asante Awuku
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yaw Asante Awuku has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Adwoa Agyei-Nkansah
Department of Medicine and Therapeutics, University of Ghana Medical School, Accra, Ghana
8 shared publications - Amelie Plymoth
European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden. 15
8 shared publications - Amoako Duah
Department of Medicine, University of Ghana Medical Centre, Accra, Ghana
8 shared publications - Hiroyuki Yamada
Division of In Vitro Diagnostics, FUJIFILM Corporation, Tokyo, Japan. 13
8 shared publications - Joshua Ayawin
Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana
8 shared publications - Ju Dong Yang
Karsh Division of Gastroenterology and Hepatology, Comprehensive Transplant Center, and Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
8 shared publications
Latest Publications
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from GALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients
ROC of GALAD scores for the detection of HCC. X axis: specificity; Y axis: sensitivity. Sensitivity #1; controls with high AFP (>400 ng/mL), high AFP-L3% (>35%), or high DCP (>2.85 ng/mL) are imputed as cases (N = 14). Sensitivity #2; controls with high AFP (>400 ng/mL), high AFP-L3% (>35%), or high DCP.
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from GALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients
ROC of GALAD scores for the detection of HCC. X axis: specificity; Y axis: sensitivity. Sensitivity #1; controls with high AFP (>400 ng/mL), high AFP-L3% (>35%), or high DCP (>2.85 ng/mL) are imputed as cases (N = 14). Sensitivity #2; controls with high AFP (>400 ng/mL), high AFP-L3% (>35%), or high DCP.
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Data from GALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide including sub-Saharan Africa. The GALAD score, derived from Gender, Age, Lens culinaris agglutinin-reactive fraction of alpha fetoprotein, Alpha fetoprotein, and Des-carboxy-prothrombin, has high accuracy in diagnosing HCC in Asia, Europe, and North America; however, it has not been validated in an African cohort. The aim of this study was to assess the performance of the GALAD score in the diagnosis of HCC in sub-Saharan Africa. Clinical data from patients with cirrhosis (n = 93) or HCC (n = 78) from outpatient hepatology clinics at three teaching hospitals in Ghana were abstracted, and serum samples were analyzed. A logistic regression model predicting HCC status based on the GALAD score was constructed to obtain the ROC curve for GALAD. The AUC with 95% confidence interval (CI) was calculated. The median GALAD score was higher among patients with HCC versus cirrhosis controls (8.0 vs. −4.1, P < 0.01). The AUC of the GALAD score for HCC detection was 0.86 (95% CI, 0.79–0.92). At a cut-off value of −0.37, the GALAD score had a sensitivity of 0.81 and a specificity of 0.86. The AUC (95% CI) was 0.87 (0.80–0.95) and 0.81 (0.67–0.94) in hepatitis B virus–positive and hepatitis B virus–negative patients, respectively. The GALAD score has a high accuracy for HCC detection. It has great potential to improve HCC surveillance in sub-Saharan Africa where imaging resources are limited.Significance:The GALAD score or its relevant modifications have the potential to aid in improving HCC surveillance efforts in low-resource settings in sub-Saharan Africa. This could enhance early detection rates of HCC and potentially improve survival rates in resource-limited settings.
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from GALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide including sub-Saharan Africa. The GALAD score, derived from Gender, Age, Lens culinaris agglutinin-reactive fraction of alpha fetoprotein, Alpha fetoprotein, and Des-carboxy-prothrombin, has high accuracy in diagnosing HCC in Asia, Europe, and North America; however, it has not been validated in an African cohort. The aim of this study was to assess the performance of the GALAD score in the diagnosis of HCC in sub-Saharan Africa. Clinical data from patients with cirrhosis (n = 93) or HCC (n = 78) from outpatient hepatology clinics at three teaching hospitals in Ghana were abstracted, and serum samples were analyzed. A logistic regression model predicting HCC status based on the GALAD score was constructed to obtain the ROC curve for GALAD. The AUC with 95% confidence interval (CI) was calculated. The median GALAD score was higher among patients with HCC versus cirrhosis controls (8.0 vs. −4.1, P < 0.01). The AUC of the GALAD score for HCC detection was 0.86 (95% CI, 0.79–0.92). At a cut-off value of −0.37, the GALAD score had a sensitivity of 0.81 and a specificity of 0.86. The AUC (95% CI) was 0.87 (0.80–0.95) and 0.81 (0.67–0.94) in hepatitis B virus–positive and hepatitis B virus–negative patients, respectively. The GALAD score has a high accuracy for HCC detection. It has great potential to improve HCC surveillance in sub-Saharan Africa where imaging resources are limited.Significance:The GALAD score or its relevant modifications have the potential to aid in improving HCC surveillance efforts in low-resource settings in sub-Saharan Africa. This could enhance early detection rates of HCC and potentially improve survival rates in resource-limited settings.
- Open Access
- 10 October 2024
- Published by American Association for Cancer Research (AACR)
Table 2 from GALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients
Optimal cut-off of the GALAD score with sensitivity and specificity
- 10 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from GALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients
Optimal cut-off of the GALAD score with sensitivity and specificity
- Open Access
- 10 October 2024
- Published by American Association for Cancer Research (AACR)
Table 5 from GALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients
Comparison of the AUC of the three different GALAD score models
- 10 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable 5 from GALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients
Comparison of the AUC of the three different GALAD score models
- Open Access
- 10 October 2024
- Published by American Association for Cancer Research (AACR)
Table 1 from GALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients
Clinical characteristics of Ghanaian cirrhosis and HCC cohort
- 10 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from GALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients
Clinical characteristics of Ghanaian cirrhosis and HCC cohort
- Open Access
- 10 October 2024
- Published by American Association for Cancer Research (AACR)
Table 3 from GALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients
Refit of the logistic regression model
- 10 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from GALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients
Refit of the logistic regression model
- Open Access
- 10 October 2024
- Published by American Association for Cancer Research (AACR)
Table 4 from GALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients
Refit of the logistic regression model using the backward selection process
- 10 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable 4 from GALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients
Refit of the logistic regression model using the backward selection process
- Open Access
- 1 October 2024
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 4 (10) , 2653-2659
GALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide including sub-Saharan Africa. The GALAD score, derived from Gender, Age, Lens culinaris agglutinin-reactive fraction of alpha fetoprotein, Alpha fetoprotein, and Des-carboxy-prothrombin, has high accuracy in diagnosing HCC in Asia, Europe, and North America; however, it has not been validated in an African cohort. The aim of this study was to assess the performance of the GALAD score in the diagnosis of HCC in sub-Saharan Africa. Clinical data from patients with cirrhosis (n = 93) or HCC (n = 78) from outpatient hepatology clinics at three teaching hospitals in Ghana were abstracted, and serum samples were analyzed. A logistic regression model predicting HCC status based on the GALAD score was constructed to obtain the ROC curve for GALAD. The AUC with 95% confidence interval (CI) was calculated. The median GALAD score was higher among patients with HCC versus cirrhosis controls (8.0 vs. −4.1, P < 0.01). The AUC of the GALAD score for HCC detection was 0.86 (95% CI, 0.79–0.92). At a cut-off value of −0.37, the GALAD score had a sensitivity of 0.81 and a specificity of 0.86. The AUC (95% CI) was 0.87 (0.80–0.95) and 0.81 (0.67–0.94) in hepatitis B virus–positive and hepatitis B virus–negative patients, respectively. The GALAD score has a high accuracy for HCC detection. It has great potential to improve HCC surveillance in sub-Saharan Africa where imaging resources are limited. Significance: The GALAD score or its relevant modifications have the potential to aid in improving HCC surveillance efforts in low-resource settings in sub-Saharan Africa. This could enhance early detection rates of HCC and potentially improve survival rates in resource-limited settings.
- 1 October 2024
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 4 (10) , 2653-2659
Open AccessGALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide including sub-Saharan Africa. The GALAD score, derived from Gender, Age, Lens culinaris agglutinin-reactive fraction of alpha fetoprotein, Alpha fetoprotein, and Des-carboxy-prothrombin, has high accuracy in diagnosing HCC in Asia, Europe, and North America; however, it has not been validated in an African cohort. The aim of this study was to assess the performance of the GALAD score in the diagnosis of HCC in sub-Saharan Africa. Clinical data from patients with cirrhosis (n = 93) or HCC (n = 78) from outpatient hepatology clinics at three teaching hospitals in Ghana were abstracted, and serum samples were analyzed. A logistic regression model predicting HCC status based on the GALAD score was constructed to obtain the ROC curve for GALAD. The AUC with 95% confidence interval (CI) was calculated. The median GALAD score was higher among patients with HCC versus cirrhosis controls (8.0 vs. −4.1, P < 0.01). The AUC of the GALAD score for HCC detection was 0.86 (95% CI, 0.79–0.92). At a cut-off value of −0.37, the GALAD score had a sensitivity of 0.81 and a specificity of 0.86. The AUC (95% CI) was 0.87 (0.80–0.95) and 0.81 (0.67–0.94) in hepatitis B virus–positive and hepatitis B virus–negative patients, respectively. The GALAD score has a high accuracy for HCC detection. It has great potential to improve HCC surveillance in sub-Saharan Africa where imaging resources are limited. Significance: The GALAD score or its relevant modifications have the potential to aid in improving HCC surveillance efforts in low-resource settings in sub-Saharan Africa. This could enhance early detection rates of HCC and potentially improve survival rates in resource-limited settings.